Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Fiche publication
Date publication
février 2018
Journal
Lancet (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier
Tous les auteurs :
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W
Lien Pubmed
Résumé
Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity.
Mots clés
Aged, Benzamides, administration & dosage, Dose-Response Relationship, Drug, Female, Humans, Lymphoma, Mantle-Cell, drug therapy, Male, Middle Aged, Protein Kinase Inhibitors, administration & dosage, Pyrazines, administration & dosage, Recurrence, Survival Analysis, Treatment Outcome
Référence
Lancet. 2018 02 17;391(10121):659-667